Lineage Cell Therapeutics (STU:BT3) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:BT3 Lineage Cell Therapeutics Inc STU:BT3
78 GF Score
Price €0.89
GF Value €1.14
! 4 Warning Signs
View Full Analysis

What is Lineage Cell Therapeutics FFO per Share?

FFO per Share only applies to REITs.

STU:BT3
78GF Score
Lineage Cell Therapeutics Inc STU:BT3
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lineage Cell Therapeutics (STU:BT3) Overvalued in 2026?

Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be undervalued. The current stock price of €0.89 is trading 22.1% below its estimated GF Value™ of €1.14.

Key valuation signals for STU:BT3:

  • FFO per Share:
  • GF Value™: €1.14 vs. price of €0.89 (22.1% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the STU:BT3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lineage Cell Therapeutics Business Description

Other Exchanges LCTX:USALCTX:Israel
Address 2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
78GF Score

Get the complete analysis for STU:BT3

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.89
Price
€1.14
GF Value